Brokerages predict that CytomX Therapeutics Inc (NASDAQ:CTMX) will post earnings of ($0.42) per share for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for CytomX Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.67) and the highest estimate coming in at $0.00. CytomX Therapeutics posted earnings of ($0.28) per share during the same quarter last year, which suggests a negative year over year growth rate of 50%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, November 6th.
According to Zacks, analysts expect that CytomX Therapeutics will report full-year earnings of ($1.58) per share for the current financial year, with EPS estimates ranging from ($2.14) to ($0.55). For the next fiscal year, analysts anticipate that the business will report earnings of ($2.11) per share, with EPS estimates ranging from ($3.72) to ($0.94). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover CytomX Therapeutics.
CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.01). The company had revenue of $21.34 million for the quarter, compared to the consensus estimate of $16.48 million. CytomX Therapeutics had a negative return on equity of 74.84% and a negative net margin of 44.46%.
In related news, insider Sean A. Mccarthy sold 13,052 shares of the company’s stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $21.86, for a total transaction of $285,316.72. Following the completion of the sale, the insider now owns 95,115 shares of the company’s stock, valued at $2,079,213.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Debanjan Ray sold 3,000 shares of the company’s stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $22.39, for a total transaction of $67,170.00. Following the sale, the chief financial officer now directly owns 8,928 shares of the company’s stock, valued at approximately $199,897.92. The disclosure for this sale can be found here. Insiders have sold 22,052 shares of company stock valued at $486,017 in the last ninety days. 8.50% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Great West Life Assurance Co. Can lifted its position in CytomX Therapeutics by 174.6% during the second quarter. Great West Life Assurance Co. Can now owns 4,943 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 3,143 shares during the period. SG Americas Securities LLC bought a new stake in CytomX Therapeutics during the second quarter worth about $119,000. WINTON GROUP Ltd bought a new stake in CytomX Therapeutics during the first quarter worth about $205,000. Xact Kapitalforvaltning AB bought a new stake in CytomX Therapeutics during the second quarter worth about $206,000. Finally, Fox Run Management L.L.C. bought a new stake in CytomX Therapeutics during the third quarter worth about $225,000. 72.05% of the stock is owned by institutional investors and hedge funds.
Shares of CytomX Therapeutics stock traded down $1.07 during trading on Friday, reaching $15.39. The company’s stock had a trading volume of 234,106 shares, compared to its average volume of 364,678. The stock has a market cap of $740.10 million, a PE ratio of -13.27 and a beta of 0.87. CytomX Therapeutics has a 52 week low of $15.09 and a 52 week high of $35.00.
About CytomX Therapeutics
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Recommended Story: Stock Split
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.